Global Viscosupplementation Market to reach USD 7.03 Billion by 2027.Global Viscosupplementation Market is valued approximately at USD 3.76 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 9.35% over the forecast period 2021-2027. Viscosupplements available for clinical efficacy and are proven to be the most effective and efficient treatment for the knee osteoarthritis. The global Viscosupplementation market is being driven by increasing prevalence of osteoarthritis among geriatric population and new product development. Furthermore, rising approvals for three-injection viscosupplements, will provide new opportunities for the global Viscosupplementation industry. For instance, according to the report of World health organization the global population aged 65 years and above is projected to grow from 7% in 2000 to 16% by year 2050, which will lead to increase in the incidence of obesity and osteoarthritis among the geriatric population. As a result, increasing prevalence of osteoarthritis among geriatric population, will serve as a catalyst for the Viscosupplementation industry in the future. However, high cost of products and side effects associated with hyaluronic acid cycles, may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global Viscosupplementation Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. The presence of a large geriatric population, which is more susceptible to disorders, such as osteoarthritis makes Asia Pacific the leading region across the world in terms of market share. Whereas Europe is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to factors, such as the growing geriatric population and increased investments by market players in the region.
Major market player included in this report are:

Sanofi
Anika Therapeutics, Inc.
Seikagaku corporation
Zimmer Biomet
Smith & Nephew PLC
Ferring Pharmaceuticals B.V
Lifecore Biomedical, LLC (Landec)
LG Life Sciences Ltd.
Fidia Farmaceutici S.p.A
F.Hoffmann-La Roche Ltd.


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:
Single Injection
Three injections
Five Injection
By End Use:
Hospitals
Orthopedic Clinics/Ambulatory Surgical Centres (ASCS)
Others


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Viscosupplementation Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors